Comparison of MRD testing with next-generation flow cytometry and next-generation sequencing
| Characteristic . | Next-generation flow cytometry . | Next-generation sequencing . |
|---|---|---|
| Requires baseline sample | No | Yes, in order to identify clone to track |
| Sensitivity | <10−5 | <10−6 |
| Sample requirements | >5 million cells (more cells to increase sensitivity to 10−6) | <2 million cells |
| Sample processing | Requires fresh sample | For Clonoseq tracking: fresh or frozen sample |
| Assessment for hemodilution | Yes | Not possible |
| Turnaround time | 2-4 days | 7 days |
| Commercial availability | Reference or experienced in-house laboratory | Clonoseq (Adaptive); LymphoTrack for in-house use |
| Characteristic . | Next-generation flow cytometry . | Next-generation sequencing . |
|---|---|---|
| Requires baseline sample | No | Yes, in order to identify clone to track |
| Sensitivity | <10−5 | <10−6 |
| Sample requirements | >5 million cells (more cells to increase sensitivity to 10−6) | <2 million cells |
| Sample processing | Requires fresh sample | For Clonoseq tracking: fresh or frozen sample |
| Assessment for hemodilution | Yes | Not possible |
| Turnaround time | 2-4 days | 7 days |
| Commercial availability | Reference or experienced in-house laboratory | Clonoseq (Adaptive); LymphoTrack for in-house use |
Table adapted from Kumar et al.9